Literature DB >> 30410212

Medical management of metastatic prostate cancer.

Amy Body1,1,2,3,4, Ganes Pranavan1,1,2,3,4, Thean Hsiang Tan1,1,2,3,4, Peter Slobodian1,1,2,3,4.   

Abstract

Entities:  

Keywords:  abiraterone; androgen deprivation therapy; chemotherapy; docetaxel; enzalutamide; prostate cancer; radium

Year:  2018        PMID： 30410212      PMCID： PMC6202297          DOI： 10.18773/austprescr.2018.046

Source DB:  PubMed          Journal:  Aust Prescr        ISSN： 0312-8008


× No keyword cloud information.
  35 in total

Review 1.  Association of androgen deprivation therapy and depression in the treatment of prostate cancer: A systematic review and meta-analysis.

Authors:  Kevin T Nead; Sumi Sinha; David D Yang; Paul L Nguyen
Journal:  Urol Oncol       Date:  2017-08-10       Impact factor: 3.498

2.  Increased survival with enzalutamide in prostate cancer after chemotherapy.

Authors:  Howard I Scher; Karim Fizazi; Fred Saad; Mary-Ellen Taplin; Cora N Sternberg; Kurt Miller; Ronald de Wit; Peter Mulders; Kim N Chi; Neal D Shore; Andrew J Armstrong; Thomas W Flaig; Aude Fléchon; Paul Mainwaring; Mark Fleming; John D Hainsworth; Mohammad Hirmand; Bryan Selby; Lynn Seely; Johann S de Bono
Journal:  N Engl J Med       Date:  2012-08-15       Impact factor: 91.245

3.  External Beam Radiation Therapy or Brachytherapy With or Without Short-course Neoadjuvant Androgen Deprivation Therapy: Results of a Multicenter, Prospective Study of Quality of Life.

Authors:  Hiram A Gay; Martin G Sanda; Jingxia Liu; Ningying Wu; Daniel A Hamstra; John T Wei; Rodney L Dunn; Eric A Klein; Howard M Sandler; Christopher S Saigal; Mark S Litwin; Deborah A Kuban; Larry Hembroff; Meredith M Regan; Peter Chang; Jeff M Michalski
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-02-22       Impact factor: 7.038

4.  Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.

Authors:  Nicholas D James; Johann S de Bono; Melissa R Spears; Noel W Clarke; Malcolm D Mason; David P Dearnaley; Alastair W S Ritchie; Claire L Amos; Clare Gilson; Rob J Jones; David Matheson; Robin Millman; Gerhardt Attard; Simon Chowdhury; William R Cross; Silke Gillessen; Christopher C Parker; J Martin Russell; Dominik R Berthold; Chris Brawley; Fawzi Adab; San Aung; Alison J Birtle; Jo Bowen; Susannah Brock; Prabir Chakraborti; Catherine Ferguson; Joanna Gale; Emma Gray; Mohan Hingorani; Peter J Hoskin; Jason F Lester; Zafar I Malik; Fiona McKinna; Neil McPhail; Julian Money-Kyrle; Joe O'Sullivan; Omi Parikh; Andrew Protheroe; Angus Robinson; Narayanan N Srihari; Carys Thomas; John Wagstaff; James Wylie; Anjali Zarkar; Mahesh K B Parmar; Matthew R Sydes
Journal:  N Engl J Med       Date:  2017-06-03       Impact factor: 91.245

Review 5.  Bisphosphonate therapy in patients under androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis.

Authors:  A Serpa Neto; M Tobias-Machado; M A P Esteves; M D Senra; M L Wroclawski; F L A Fonseca; R B Dos Reis; A C L Pompeo; A D Giglio
Journal:  Prostate Cancer Prostatic Dis       Date:  2011-09-06       Impact factor: 5.554

6.  Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial.

Authors:  Daniel A Galvão; Dennis R Taaffe; Nigel Spry; David Joseph; Robert U Newton
Journal:  J Clin Oncol       Date:  2009-11-30       Impact factor: 44.544

7.  Development of a second-generation antiandrogen for treatment of advanced prostate cancer.

Authors:  Chris Tran; Samedy Ouk; Nicola J Clegg; Yu Chen; Philip A Watson; Vivek Arora; John Wongvipat; Peter M Smith-Jones; Dongwon Yoo; Andrew Kwon; Teresa Wasielewska; Derek Welsbie; Charlie Degui Chen; Celestia S Higano; Tomasz M Beer; David T Hung; Howard I Scher; Michael E Jung; Charles L Sawyers
Journal:  Science       Date:  2009-04-09       Impact factor: 47.728

8.  Importance of continued testicular suppression in hormone-refractory prostate cancer.

Authors:  C D Taylor; P Elson; D L Trump
Journal:  J Clin Oncol       Date:  1993-11       Impact factor: 44.544

9.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Authors:  Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

10.  Intermittent versus continuous androgen deprivation in prostate cancer.

Authors:  Maha Hussain; Catherine M Tangen; Donna L Berry; Celestia S Higano; E David Crawford; Glenn Liu; George Wilding; Stephen Prescott; Subramanian Kanaga Sundaram; Eric Jay Small; Nancy Ann Dawson; Bryan J Donnelly; Peter M Venner; Ulka N Vaishampayan; Paul F Schellhammer; David I Quinn; Derek Raghavan; Benjamin Ely; Carol M Moinpour; Nicholas J Vogelzang; Ian M Thompson
Journal:  N Engl J Med       Date:  2013-04-04       Impact factor: 91.245
View more
  2 in total

1.  Novel therapeutic compounds for prostate adenocarcinoma treatment: An analysis using bioinformatic approaches and the CMap database.

Authors:  Kai Li; Jingyuan Fan; Xinyi Qin; Qingjun Wei
Journal:  Medicine (Baltimore)       Date:  2020-12-18       Impact factor: 1.817

2.  Development of [225Ac]Ac-PSMA-I&T for Targeted Alpha Therapy According to GMP Guidelines for Treatment of mCRPC.

Authors:  Eline L Hooijman; Yozlem Chalashkan; Sui Wai Ling; Figen F Kahyargil; Marcel Segbers; Frank Bruchertseifer; Alfred Morgenstern; Yann Seimbille; Stijn L W Koolen; Tessa Brabander; Erik de Blois
Journal:  Pharmaceutics       Date:  2021-05-13       Impact factor: 6.321
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.